ImmunityBio, Inc.
No SEC Form 4 filings for $IBRX in the last 30 days.
See all $IBRX insider activity →ImmunityBio (IBRX) is in focus ahead of founder Patrick Soon-Shiong’s AUA 2026 talk, where he plans to discuss challenges for papillary bladder cancer patients, including ongoing BCG shortages. The company says Merck (MRK) is the only global BCG supplier and that its Anktiva is approved only with BCG. IBRX shares were down about 3% Friday.
ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ibrx-202684x8kexhibit991.htm EX-99.1 Document EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year a
Emirates Drug Establishment approved ImmunityBio’s (NASDAQ:IBRX) ANKTIVA in the UAE for BCG-unresponsive non-muscle invasive bladder cancer, allowing a 0.4 mg intravesical dose with BCG across the full NMIBC spectrum. It also approved a 1.2 mg subcutaneous dose with checkpoint inhibitors for metastatic NSCLC. QUILT-3.032 reported 71% CIS complete response; QUILT-3.055 median OS was 14.6 months. IBRX shares rose 5.49% to $7.20.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IBRX (ImmunityBio, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent IBRX coverage spans insider activity, regulation and market movers.
Near-term catalyst is the Saturday AUA discussion, but the article does not add a new FDA decision or new clinical/regulatory datapoint.
The filing adds a concrete FDA regulatory timeline while confirming strong commercial momentum, which can re-rate near-term probability-weighted outcomes for ANKTIVA.
UAE approval broadens ANKTIVA’s label and supports incremental commercial optionality in bladder cancer and checkpoint-refractory NSCLC.
UAE approval expands ANKTIVA’s regulatory footprint and adds new commercial optionality in two oncology settings.
Approval-driven sentiment is positive and can extend into the session if traders extrapolate broader adoption or reimbursement momentum.
alphai scores every news story that mentions IBRX with an AI model for sentiment and relevance, and aggregates insider trades from ImmunityBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ImmunityBio (IBRX) is in focus ahead of founder Patrick Soon-Shiong’s AUA 2026 talk, where he plans to discuss challenges for papillary bladder cancer patients, including ongoing BCG shortages. The company says Merck (MRK) is the only global BCG supplier and that its Anktiva is approved only with BCG. IBRX shares were down about 3% Friday.
4 min readImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ibrx-202684x8kexhibit991.htm EX-99.1 Document EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year a
6 min readEmirates Drug Establishment approved ImmunityBio’s (NASDAQ:IBRX) ANKTIVA in the UAE for BCG-unresponsive non-muscle invasive bladder cancer, allowing a 0.4 mg intravesical dose with BCG across the full NMIBC spectrum. It also approved a 1.2 mg subcutaneous dose with checkpoint inhibitors for metastatic NSCLC. QUILT-3.032 reported 71% CIS complete response; QUILT-3.055 median OS was 14.6 months. IBRX shares rose 5.49% to $7.20.
3 min readImmunityBio (NASDAQ:IBRX) shares rose about 7.5% after the UAE granted marketing authorization for ANKTIVA. Approval covers NMIBC with BCG (based on QUILT-3.032) and metastatic NSCLC with immune checkpoint inhibitors (QULT-3.055). The UAE authorization expands ANKTIVA’s regulatory footprint to 34 countries.
4 min readU.S. stock futures were higher in early Thursday trade as investors digested tech earnings, fresh military action in the Middle East, an increasingly divided Federal Reserve and crucial inflation data due later today. Microsoft and Meta earnings highlighted that AI infrastructure spending will continue at an enormous pace. However, investors cheered Microsoft’s reassurance on its $35.8B capex efficiency, and punished Meta’s elevated FY26 capex outlook.
6 min readU.S. stock index futures rose overnight after the Fed held benchmark rates steady, though investors cited elevated inflation concerns. The Dow, S&P 500 and Nasdaq fell on Wednesday. Microsoft earnings beat and shares rose, while Meta and Qualcomm declined. Oil rose on U.S.-Iran retaliation. ImmunityBio jumped on UAE approval for Anktiva.
7 min readCohen Cheryl sold 131,210 shares of ImmunityBio, Inc. (IBRX) at $9.50 ($1.25M total) on 2026-07-02 under a Rule 10b5-1 trading plan.
1 min readSelecky Christobel sold 159,478 shares of ImmunityBio, Inc. (IBRX) at $9.02 ($1.44M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readSelecky Christobel sold 96,722 shares of ImmunityBio, Inc. (IBRX) at an average of $9.01 ($9.00–$9.01, $0.87M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ibrx-20260609 FALSE 0001326110 0001326110 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read
